Follow-up study of patients with rheumatoid arthritis who treated infliximab for 1 year and did not reach a clinical remission in RRRR Study

Follow-up study of patients with rheumatoid arthritis who treated infliximab for 1 year and did not reach a clinical remission in RRRR Study - Remission induction by Raising the dose of Remicade in RA Extension study (RRRR-EX Study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007539

Enrollment

108

Registered

2012-04-01

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who did not reach a clinical remission at the time of 54 weeks from first administration of IFX in RRRR Study 2)Patients who continue treatment with IFX administration after failing to reach a clinical remission 3)Written informed consent

Exclusion criteria

Exclusion criteria: 1)Patients who discontinued IFX treatment prior to 54 week from the first administration of IFX in the RRRR Study 2) Patients who are inadequate to enter this trial due to the other reasons by physician's judgments

Design outcomes

Primary

Measure	Time frame
Proportion of clinical remission 1 year after enrolling in RRRR-RX Study	—

Countries

Japan

Contacts

Public ContactNao Horie

Hokkaido University Hospital Translational Research and Clinical Trial Center

RRRR@pop.med.hokudai.ac.jp011-706-7735

Outcome results